Designing a Phase 1 Single- and Multiple-Ascending-Dose Study of a Humanized Anti-APRIL Monoclonal Antibody in Healthy Adults: Starting-Dose Derivation, Escalation, and Protocol Synopsis
A humanized antibody that neutralizes a proliferation-inducing ligand (APRIL) is designed to reduce pathogenic immunoglobulin production in B-cell-driven diseases, and its first-in-human study must show that the starting dose sits well below any dose that could cause harm to a healthy volunteer. This article develops a hypothetical Phase 1 randomized, double-blind, placebo-controlled study with a single-ascending-dose part (four cohorts) and a multiple-ascending-dose part (two cohorts dosed every four weeks for three doses) in healthy adults. It derives a 40 mg subcutaneous starting dose from an assumed 13-week cynomolgus monkey no-observed-adverse-effect level of 50 mg/kg/week, a maximum recommended starting dose of about 350 mg, and a further 8.75-fold margin, escalating by doubling to 320 mg with sentinel dosing and Safety Review Committee review. The synopsis covers 48 planned participants (up to 58 with replacements), pharmacokinetic, pharmacodynamic, and immunogenicity endpoints, dose-limiting rules, a schedule of events, and a descriptive statistical analysis. The article corrects a common labeling error, describing a doubling schedule as half-log, and states which values are assumptions.Keywords: first-in-human; monoclonal antibody; APRIL; single ascending dose; multiple ascending dose; maximum recommended starting dose; ICH S6(R1); sentinel dosing
Authors
- Peivand Pirouzi
- Patricia Angelique Mallari
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426497
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00